MAGELLAN LONGEVITY
HomeResearchStudy library › Can sulforaphane, delivered as a broccoli sprout extract (BSE)…
Study summary · Metabolic health, glucose & body composition

Can sulforaphane, delivered as a broccoli sprout extract (BSE), reduce hepatic gluconeogenesis and improve fasting blood glucose in individuals with prediabetes?

In one paragraph

Broccoli Sprout Sulforaphane, a randomized, double-blind, placebo-controlled trial in 35 participants (Nat Microbiol 2025, PMID 39929977) — BSE did not meet the prespecified primary outcome of a 0.3 mmol/l reduction. The primary outcome was not met for the overall study population.

Source: Nat Microbiol 2025, PMID 39929977 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

Nat Microbiol · 2025 · PMID 39929977 · DOI 10.1038/s41564-025-01932-w

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Broccoli sprout extract did not significantly lower fasting blood glucose in all prediabetic individuals, but a subgroup with specific characteristics showed a more positive response linked to gut microbiota.

The question

Can sulforaphane, delivered as a broccoli sprout extract (BSE), reduce hepatic gluconeogenesis and improve fasting blood glucose in individuals with prediabetes?

What they tested

Sulforaphane, provided as a broccoli sprout extract, will reduce fasting blood glucose in individuals with prediabetes.

How they did it

A randomized, double-blind, placebo-controlled trial was conducted with drug-naive individuals with prediabetes. Participants received either BSE (n=35) or placebo (n=39) once daily for 12 weeks. The primary outcome was a 0.3 mmol/l reduction in fasting blood glucose compared to placebo from baseline to week 12. Gastrointestinal side effects were monitored.

What they found

BSE did not meet the prespecified primary outcome of a 0.3 mmol/l reduction. The overall effect in individuals with prediabetes was a 0.2 mmol/l reduction in fasting blood glucose. Exploratory analyses identified a subgroup of individuals with mild obesity, low insulin resistance, and reduced insulin secretion who had a 0.4 mmol/l reduction. Gut microbiota analysis showed responders had a different gut microbiota composition, with a higher abundance of a Bacteroides-encoded transcriptional regulator linked to sulforaphane activation and serum concentration.

Fasting Blood Glucose Reduction with Broccoli Sprout Extract
Values shown: Fasting Blood Glucose Reduction (mmol/l)
Overall Prediabetes Group0.2
Responders Subgroup0.4

Reduction in fasting blood glucose (mmol/l) from baseline to week 12 for the overall prediabetes group and the identified responder subgroup.

What it means

While BSE did not meet its primary endpoint for the overall prediabetes population, a subgroup of individuals with specific pathophysiological and gut microbiota characteristics showed a more pronounced reduction in fasting blood glucose. This suggests a combined influence of host pathophysiology and gut microbiota on the metabolic response to sulforaphane.

Limitations

The primary outcome was not met for the overall study population. The findings regarding subgroups and gut microbiota are based on exploratory analyses and require confirmation in future trials.

“reduction in fasting blood glucose compared with placebo”— from the published abstract, Nat Microbiol 2025

The paper at a glance

Magellan’s evidence labelsulforaphane reduces hepatic gluconeogenesis (our label for this citation — see PubMed for the paper’s own title and authors)
JournalNat Microbiol
Year2025
PMID39929977 ↗
DOI10.1038/s41564-025-01932-w ↗
TopicMetabolic health, glucose & body composition

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Broccoli Sprout Sulforaphane

Human trials indicate that concentrated broccoli-sprout sulforaphane can modestly lower fasting blood glucose and glycated hemoglobin, most clearly in obese or dysregulated type 2 diabetes and in a subset of people with prediabetes;

Broccoli Sprout Sulforaphane

Sulforaphane is an isothiocyanate phytochemical formed when the plant enzyme myrosinase acts on…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Can sulforaphane, delivered as a broccoli sprout extract (BSE), reduce hepatic gluconeogenesis and improve fasting blood glucose in individuals with prediabetes? [Plain-English summary of Nat Microbiol 2025, PMID 39929977, DOI 10.1038/s41564-025-01932-w]. Magellan Longevity. https://magellanlongevity.com/study/s103.html
BibTeX
@misc{magellan_s103, title = {Can sulforaphane, delivered as a broccoli sprout extract (BSE), reduce hepatic gluconeogenesis and improve fasting blood glucose in individuals with prediabetes?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/s103.html}}, note = {Plain-English summary of PubMed PMID 39929977; DOI 10.1038/s41564-025-01932-w; Nat Microbiol 2025. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/s103.html

Related studies in the Magellan library

All 22 Magellan summaries on metabolic health, glucose & body composition →

How this summary was made. Every section above restates what the published abstract of PMID 39929977 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.